Program
LY4005130
A development code.
In Eli Lilly's pipeline, XCL1/XCL2 neutralizing antibody
. Its studies are mostly in Alopecia Areata · Vitiligo, led by Eli Lilly.
Furthest: phase 2, since Apr 9, 20263 company-led studies, 2 open or runningNext primary completion: May 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 32 open or running | phase 2since Apr 9, 2026 | Nov 14, 2024 | May 2027phase 2 · NCT07533019 |
- Named in Eli Lilly’s own pipeline as
XCL1/2 Neutralizing Antibody
, phase 2, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 14, 2024First study: phase 1 study in HealthyFirst studyNCT06690996 · 110 enrolled · United States
- Apr 9, 20262 phase 2 studiesPhase 2 reachedNCT07533019, NCT07533006
Ahead
- May 2027Primary completion: phase 2 study in VitiligoNCT07533019
- Jun 2027Primary completion: phase 2 study in Alopecia AreataNCT07533006
TargetBeta
“XCL1/XCL2 neutralizing antibody”the company's pipeline, read by Claude · source
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07533019Vitiligo · United States, Belgium, Canada and more | 2 | Recruiting | May 2027 | 66 |
| NCT07533006Alopecia Areata · United States, Canada, China and more | 2 | Recruiting | Jun 2027 | 65 |
| NCT06690996Healthy · United States | 1 | Completed | Apr 28, 2026 | 110 |
How it is read
Names in the registry
- “LY4005130”, 4 entries
Codes read as this program: LY4005130.
Conditions, from the studies’ own filings
- Alopecia Areata, 1 study
- Vitiligo, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.